CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3β/β-catenin pathway

Table 1 Association between CD58 expression and clinicopathological factors of 69 patients in HCC

Clinicopathological factors	High CD58 (n = 55)	Low CD58 (n = 14)	p value
Age
≥ 60	40	8	0.2579
< 60	15	6	0.2579
Sex
Male	44	4	0.0002***
Female	11	10	0.0002***
Tumor size
> 5 cm	27	2	0.0185*
≤ 5 cm	28	12	0.0185*
Differentiation level
Low/Middle	48	8	0.0101*
High	7	6	0.0101*
AFP (μg /L)
< 400	37	11	0.4120
≥ 400	18	3	0.4120
Satellite focus
With	18	0	0.0128*
Without	37	14	0.0128*
Tumor thrombus
With	28	2	0.0136*
Without	27	12	0.0136*
Liver cirrhosis
With	21	4	0.5042
Without	34	10	0.5042
Chronic hepatitis
With	18	4	0.9999
Without	37	10	0.9999

ISSN: 1479-5876